All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Patient-reported disease impact at 1 year with bimekizumab treatment in PsA
By Ella Dixon
|
The long-term effects of PsA and its treatments can impact social, emotional, and physical aspects of a patient’s quality of life. For example, symptoms of PsA, such as pain and fatigue, can prevent patients from engaging in their normal activities. Therefore, treatments should aim to improve patient quality of life by reducing symptom impact. A post hoc analysis assessed the efficacy of bimekizumab, an IL-17 inhibitor, in reducing patient-reported disease impact, using 1-year data from the phase III trials BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581). Findings were published by Gossec et al. in Oxford Rheumatology. |
| Key learnings |
|
A clinically meaningful improvement (≥3-point decrease) in disease impact, measured by PsAID-12 total score, was achieved by 49.0% of bimekizumab-treated patients and 44.4% of those who switched to bimekizumab from placebo at Week 52 in BE OPTIMAL. In BE COMPLETE, this was achieved by 48.5% and 40.6% of bimekizumab- and placebo/bimekizumab-treated patients, respectively. |
|
More bimekizumab-treated patients achieved clinically meaningful improvements in all single-item PsAID-12 domains compared with placebo. The highest proportions of improvements were seen in the skin problems domain. |
|
Patients treated with bimekizumab experienced sustained improvements from Week 4 to Week 52 in PsAID-12 pain, fatigue, and skin problems, which were the most impacted domains at baseline. At 1 year, 35.3–47.8% of patients experienced minimal or no symptom impact (PsAID-12 total score ≤1.15). |
|
Bimekizumab offers a promising therapeutic option for patients with PsA, not only in terms of efficacy and safety, but also in providing clinical benefit to patients, with rapid improvement in symptoms and health-related quality of life. |
Abbreviations: IL, interleukin; PsA, psoriatic arthritis; PsAID-12, 12-item Psoriatic Arthritis Impact of Disease.
- Gossec L, Orbai A-M, de Wit M, et al. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies. Rheumatology (Oxford).2024;63(9):2399-2410. DOI: 1093/rheumatology/keae277
More about...
Your opinion matters
4 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox